Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 17/20 | 0.49 |
| ▸ | PDE4A | P27815 | 14/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | XBP1 | P17861 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4046399 | 0.92 | POLB (0.51) | POLBOPRK1RXFP1PDE4BPDE4A | |
| SCHEMBL4049204 | 0.90 | POLB (0.51) | POLBOPRK1RXFP1PDE4BPDE4A | |
| SCHEMBL4045956 | 0.82 | PDE4B (0.57) | POLBOPRK1RXFP1PDE4BPDE4A | |
| SCHEMBL4045515 | 0.81 | POLB (0.52) | POLBOPRK1RXFP1PDE4BPDE4A | |
| SCHEMBL4049402 | 0.80 | PDE4B (0.67) | POLBPDE4BPDE4APDE4D | |
| SCHEMBL4045443 | 0.79 | PDE4B (0.57) | POLBOPRK1RXFP1PDE4BPDE4A | |
| SCHEMBL4046251 | 0.79 | PDE4B (0.61) | POLBOPRK1RXFP1PDE4BPDE4A | |
| SCHEMBL4049422 | 0.78 | PDE4B (0.56) | POLBOPRK1RXFP1PDE4BPDE4A | |
| SCHEMBL4047423 | 0.78 | PDE4B (0.58) | POLBPDE4BPDE4APDE4DKDM4E | |
| SCHEMBL4045473 | 0.78 | POLB (0.47) | POLBOPRK1RXFP1PDE4BPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1819710-B1 | NEW PYRIDOTHIENOPYRIMIDINE DERIVATIVES | ALMIRALL LAB (ES) | 2009-03-11 | — | — | EP | disclosed |
| US-20090029955-A1 | Pyridothienopyrimidine Derivatives | ALMIRALL PRODESFARMA S.A. (ES) | 2009-01-29 | — | — | US | disclosed |
| EP-1819710-A1 | NEW PYRIDOTHIENOPYRIMIDINE DERIVATIVES | Laboratorios Almirall, S.A. (ES) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006058724-A1 | NEW PYRIDOTHIENOPYRIMIDINE DERIVATIVES | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029955-A1 | Pyridothienopyrimidine Derivatives | PNPO, PDE4A, DPYD | POLB 378/4885OPRK1 2590/4885RXFP1 2816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.